The Latest DOJ Reason for Refusing to Turn Over Biden-Hur Audio Tapes Is...
Is Politico Serious With This Headline About Alvin Bragg?
How the Crowd Reacted When Donald Trump Appeared at UFC 302
CNN Senior Legal Analyst Tears Into Judge Over This Aspect of the Trump...
Democrats Deserve Everything Bad That Comes Their Way…And More
The Trump VP Will Be…
Democrats’ Bogus Lawfare Takedowns Rooted In Fear and Loathing
A Quick Bible Study Vol. 220: What the Bible Says About Love
If Ignorance is Bliss, with the Trump Verdict, Liberals Are Euphoric
Mitt Romney Has Two Words for Alvin Bragg
Democrat Urges Gov. Hochul to Pardon Trump for the Sake of 'Our Country'
Bernie Moreno Pressures Dem Sherrod Brown to Rescind Biden Endorsement After Trump Verdict
DeSantis: Trump Hasn't Lost Voting Rights In Florida
Here's Where Texas Authorities Found 27 Illegal Aliens
Why It's Even More Egregious That Biden Is Still Bragging About Defying SCOTUS...
OPINION

West Virginia on the Right Track to Lower Drug Costs, But is it Enough?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
Advertisement
Advertisement
Advertisement
AP Photo/Matt Rourke

The GOP-controlled House of Delegates in West Virginia recently unanimously passed a bill that would require pharmacy benefit managers (PBM) to share the rebates they receive from drug companies with consumers at the point of purchase. The bill now goes to the state Senate.

Advertisement

Pharmacy benefit managers were created to administer drug benefits for health plans including commercial, employee and retiree plans and Medicare Part D.  In 2003, the PBM industry secured safe harbor status from Congress that exempted them from criminal prosecution for taking rebates from drug manufacturers. 

Essentially, PBMs can collect these kickbacks and give certain medications access to the millions of insured lives they manage over another manufacturer’s products based on how much the companies pay them. The PBMs’ priority shifted from the payer (health plans) to the seller (drug manufacturers) and created a conflict of interest. 

Patients may find the cost of their medications drastically increase due to a change in formulary tiering set by the pharmacy benefit manager. A skewed business practice emerged where PBMs are paid a percentage of the cost of the utilized drugs they manage which increases the compensation they receive for higher-priced drugs. Keep in mind that PBMs do no research and development, manufacturing or distribution. 

The West Virginia bill is admirable in that state legislators want to address the escalating price of prescription drugs and lower the out-of-pocket costs for consumers, but is it enough? AMAC – the Association of Mature Americans, along with a coalition of physician and patient advocates are working together to see the safe harbor status repealed and the middleman money removed completely from the outpatient prescription drug supply chain.

Advertisement

Drug manufacturers’ list prices are negatively affected by the kickbacks they must pay to PBMs. Removing the middleman money and the resulting many billions of dollars saved in drug costs seems like a sensible place to start the forthcoming debate on health care reform.  

Andrew Mangione is Senior Vice President at AMAC Action, the advocacy arm of AMAC – the Association of Mature American Citizens.  AMAC represents more than 2 million members and stands for fiscal responsibility. He writes on health care issues, among other concerns.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos